Second-Line Intraperitoneal Chemotherapy for Recurrent Epithelial Ovarian, Tubal and Peritoneal Cancer: A Propensity Score-Matching Study

Publisher： Karger

E-ISSN： 1421-9794|61|5|240-248

ISSN： 0009-3157

Source： Chemotherapy, Vol.61, Iss.5, 2016-03, pp. : 240-248

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Safety and Outcome of Patients Treated with a Modified Outpatient Intraperitoneal Regimen for Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer

By  

Chemotherapy, Vol. 59, Iss. 4, 2014-01 ,pp. : 251-259

Karger

Access to resources Recommend Favorite

Combination Chemotherapy with Irinotecan and Ifosfamide as Second-Line Treatment of Refractory or Sensitive Relapsed Small Cell Lung Cancer: A Phase II Study

By  

Chemotherapy, Vol. 49, Iss. 4, 2003-07 ,pp. : 200-205

Karger

Access to resources Recommend Favorite

Efficacy of Docetaxel as a Second-Line Chemotherapy for Thymic Carcinoma

By  

Chemotherapy, Vol. 50, Iss. 6, 2004-12 ,pp. : 279-282

Karger

Access to resources Recommend Favorite

Prognostic Factors for the Selection of Patients Eligible for Second-Line Chemotherapy in Advanced Biliary Tract Cancer

By  

Chemotherapy, Vol. 60, Iss. 2, 2015-02 ,pp. : 91-98

Karger

Access to resources Recommend Favorite

Phase I/II Trial of Irinotecan and S-1 Combination Chemotherapy as a Second-Line Treatment for Advanced Colorectal Cancer

By  

Chemotherapy, Vol. 59, Iss. 5, 2014-05 ,pp. : 338-343

Karger

Access to resources Recommend Favorite